The Ministry of Health, Labor and Welfare (MHLW) appears to be ready to begin post-launch drug price adjustments based on cost-effectiveness assessments (CEAs) for the first time since the system was introduced in April 2019. As price tweaks will be…
ORGANIZATION
JPMA Renews Call for Post-Launch Innovation Review in 2021 Proposal
The Japan Pharmaceutical Manufacturers Association (JPMA) has incorporated a post-launch mechanism that could be described as “innovation re-pricing” in its policy proposal in 2021, calling for the re-evaluation of medicines that are on the market after a certain period of…
To read the full story
ORGANIZATION
- EFPIA Issues Proposals for Japanese CEA System, Says “Cannot Accept” Expansion without Corrective Steps
April 21, 2021
- Regulations for DX, Pre-Symptomatic Disease Up for JPMA Committee Discussion
April 20, 2021
- Asia Trade Groups Discuss Regional Differences in Nonclinical Evaluations of Human Cell Products
April 20, 2021
- JGA Bitterly Reprimands Kobayashi Kako for Application Document Fabrication
April 20, 2021
- Asian Pharma Groups Agree to Ensure Smooth Drug Reviews amid COVID-19 Crisis
April 16, 2021
Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
After decades in recruitment, I say from experience that there’s a particular way to attract candidates to a given role. Do it right, and you’ll have talent chasing you. Get it wrong, and you’ll be left listening to the crickets…